SPYGLASS
PHARMA

Bimatoprost Drug Pad-IOL System Clinical Update

Dr. Malik Y. Kahook

November 8, 2025 (IGC, Salt Lake City)

Outline:

- Bimatoprost Drug Pad-IOL System (BIM-IOL System) Overview
- 24-month First-in-Human (FIH) Study Data
- 36-month FIH Study Data
- 3-month Phase 1/2 Study Data
- Summary

The BIM-IOL System aims to deliver a first-in-class solution that addresses both cataracts and elevated IOP in a single, streamlined intervention




SPYGLASS
PHARMA™

FIH Feasibility Trial Design

Single center prospective trial to evaluate the safety and efficacy of the BIM-IOL System in patients previously diagnosed with OAG or OHT and a concomitant cataract and who were taking between one and three topical IOP-lowering medications

STUDY METHOD

23 EVALUABLE PATIENTS

- Baseline washout of all IOP-lowering medications
- Sequentially assigned 1:1:1

100% of patients off drops at 24 months

FIH FEASIBILITY TRIAL RESULTS – IOP LOWERING

Mean IOP Reduction Sustained over 24 Months Across All Doses



24 MONTHS POST-OP

- All patients off topical IOP-lowering therapy
- 42% mean IOP reduction across all three doses
- 100% of patients with BCDVA ≥ 20/30
- AE profile is comparable to routine cataract surgery

95% of patients off drops at 36 months

FIH FEASIBILITY TRIAL RESULTS – IOP LOWERING

Mean IOP Reduction Sustained over 36 Months Across All Doses

N = 21 *



36 MONTHS POST-OP

- 95% of patients off topical IOP-lowering therapy
- 37% mean IOP reduction across all three doses
- 100% of patients with BCDVA ≥ 20/30
- AE profile is comparable to routine cataract surgery

*Two subjects were discontinued prior to the 36-Month Visit: one subject withdrew consent after moving outside the country and one subject was discontinued after receiving a pancreatic cancer diagnosis and was undergoing palliative care.

Phase 1/2 Trial Design

Prospective, multicenter, randomized, double-masked, controlled Phase 1/2 clinical trial to evaluate the safety and efficacy of the BIM-IOL System in patients with OAG or OHT, compared to a control group receiving a commercially available IOL followed by daily administration of timolol IOP-lowering eye drops.



- Primary efficacy endpoint:
  Time matched (8 a.m. and 10 a.m.) IOP reduction at 2, 6 and 12 weeks

- Secondary endpoints include:
  IOP reduction out to 3 years
  Visual performance
  Typical safety assessments for both medication and IOL

Sustained IOP Reduction at 3 Months

PHASE 1/2 TRIAL EFFICACY RESULTS – IOP LOWERING (INTERIM ANALYSIS)

MEAN IOP BY VISIT – 8 A.M.



MEAN IOP BY VISIT – 10 A.M.



~37%

Mean IOP reduction observed across both BIM-IOL System doses at 3 months

Drops Eliminated for 97% of BIM-IOL Patients

PHASE 1/2 TRIAL EFFICACY RESULTS – IOP MEDICATIONS (INTERIM ANALYSIS)



97%

Patients who received the BIM-IOL completely **drop-free** at 3 months

*All Control patients are prescribed topical timolol, per protocol.

Comparable Visual Performance to Industry Standard Monofocal IOL

PHASE 1/2 TRIAL EFFICACY RESULTS – VISUAL ACUITY (INTERIM ANALYSIS)



20/20

All arms mean BCDVA of 85-86 letters (~20/20)

100%

All patients BCDVA 20/40 or better

Safety Assessment at 3 Months (Interim Analysis)

- Overall safety results were comparable to routine cataract surgery.
- Adverse event (AEs) rates were similar across the 78 mcg (35.3%), the 39 mcg (39.1%) and the control (33.3%) groups.
- No serious ocular AEs were observed.

SUMMARY

- SpyGlass BIM-IOL System is tackling the patient adherence burden of glaucoma drops at the point of cataract surgery with a single, streamlined intervention
- 36-month FIH data demonstrates sustained IOP reduction (37%), eliminates need for drops (95%), and improves vision (100% ≥ 20/40)
- 3-month Phase 1/2 data demonstrates sustained IOP reduction (37%), eliminates need for drops (97%), and improves vision (100% ≥ 20/40)
- Safety profile of BIM-IOL System to date is comparable to routine cataract surgery
- First patients randomized in our Phase III clinical program planned for Q4 this year

SPYGLASS PHARMA™

QUESTIONS?

SPYGLASS PHARMA™